Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) for the lead drug candidate Dupixent (dupilumab) for the treatment of patients with prurigo nodularis.

The regulatory agency has assigned Priority Review for the application and set a PDUFA target action date of Sept. 30, 2022. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.